Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-569-3 | CAS number: 26266-58-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: other routes
Administrative data
- Endpoint:
- short-term repeated dose toxicity: other route
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Basic data given (analytical purity of test substance not specified, intravenous application).
Data source
Reference
- Reference Type:
- publication
- Title:
- Study on subacute toxicity of intravenous sorbitan trioleate (STO) in Wistar rats
- Author:
- Yamamoto, H. et al.
- Year:
- 1 983
- Bibliographic source:
- The Journal of Toxicological Sciences Vol. 8, 301-310
Materials and methods
- Principles of method if other than guideline:
- Subacute toxicity of the test substance in rats was investigated after intravenous injection of 12.5, 50 and 200 mg/kg bw/d.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Anhydro-D-glucitol trioleate
- EC Number:
- 247-569-3
- EC Name:
- Anhydro-D-glucitol trioleate
- Cas Number:
- 26266-58-0
- Molecular formula:
- C60H108O8
- IUPAC Name:
- 1,4-anhydro-2,3,6-tri-O-oleoyl-L-iditol
- Details on test material:
- - Name of test material (as cited in study report): Sorbitan trioleate
- Physical state: thin yellowish and oily
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 5 weeks
- Weight at study initiation: males 106-118 g, females 87-96 g
- Housing: individually
- Diet (ad libitum): commercial diet (Oriental Yeast Co. Ltd)
- Water (ad libitum): tap water
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 1
- Humidity (%): 55 ± 10
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- other: hydrogenated castor oil and distilled water
- Details on exposure:
- The test compound was injected into the tail vein of rats.
- Duration of treatment / exposure:
- 35 days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
12.5, 50, 200 mg/kg bw/d
- No. of animals per sex per dose:
- 10
- Control animals:
- other: animals treated with 0.4 mL/100 g of saline or with 0.4 mL/100 g of 10% HCO-60
- Details on study design:
- - Dose selection rationale: acute toxicity test with a single intravenous injection of the test substance
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
WATER CONSUMPTION: Yes
HAEMATOLOGY: Yes
- Parameters checked: red and white blood cells, hematocrit, hemoglobin content, platelet count, prothrombin time, reticulocyte count, hemogram
CLINICAL CHEMISTRY: Yes
- Parameters checked: GOT, GPT, Al-pase, BUN, creatinine, total protein, albumin/globulin, glucose, total cholesterol, albumin, sodium, potassium, calcium, chloride
URINALYSIS: Yes
- Parameters checked: pH, protein, glucose, keton body, bilirubin, urobilinogen, occult blood, specific gravity, natrium, potassium, chloride, creatinine, colour, clearness - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, all rats were necropsied and the following organs were weighed: brain, pituitary, thyroid, thymus, heart, lung, kidney, spleen, pancreas, liver, adrenal, stomach, intestine, mesenteric lymph node, submaxillary gland, testis, prostate, uterus, ovary, bladder, one marrow, eye ball and tail
HISTOPATHOLOGY: Yes, the following organs were fixed in 10% formalin and embedded in paraffin: brain, pituitary, thyroid, thymus, heart, lung, kidney, spleen, pancreas, liver, adrenal, stomach, intestine, mesenteric lymph node, submaxillary gland, testis, prostate, uterus, ovary, bladder, one marrow, eye ball and tail. The embedded sections were cut in 3-5 µm thick and stained with hematoxylin and eosin, periodic acid-Schiff, elastica Van-Gieseon, azan-Mallory, congo red and oil-red O. - Statistics:
- All data were analysed statistically by the Student t-test.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- RBC, Hb and Ht decreased in the 200 mg/kg bw dose group of both sexes compared to controls
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- significant increase of total cholesterol in high dose group and both sexes; some increases and decreases in different parameters, see details on results
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- most prominent effect was an increase in spleen weights in animals of both sexes of the high dose group; some changes in weight of other organs, see details on results
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- changes in spleen and liver were observed in the highest dose group and both sexes
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- major histological changes were observed in the lung, spleen, liver, bone marrow and injection site of the tail
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No abnormalities were observed in the control as well as experimental groups.
BODY WEIGHT AND WEIGHT GAIN
No significant effect.
FOOD CONSUMPTION
No significant effect.
WATER CONSUMPTION
No significant effect.
HAEMATOLOGY
The level of RBC, Hb and Ht decreased in the 200 mg/kg bw dose group of both sexes compared to controls. The values of prothrombin time (PT) and reticulocyte count (Rec) were also significantly increased in the same dose group of both sexes, suggesting that these rats were slightly anemic. The following effects were observed in the other groups, but since there was no dose dependancy, they were not assumed to be treatment-related: signficant increase in WBC and neutrophil values in males of the 12.5 mg/kg bw dose group, signficant increase in Rec in males of the control group and 50 mg/kg bw dose group, sigfnificant decrease in neutrophils in female animals of the 50 mg/kg bw dose group.
CLINICAL CHEMISTRY
A significant increase in total cholesterol was noted in the 200 mg/kg bw dose group of both sexes. In the same experimental group, values of Alp, BUN, Alb, A/G, sodium, chloride and creatinine were significantly decreased, and females of the same group also showed significant decreases in GOT and GOP. Moreover, significant increases or decreases in Alp, total cholesterol, creatinine and chloride of male and GOT, GPT and A/G of female were also found in the other experimental groups, however, these values were all within the normal range.
URINALYSIS
Only in the males of the 12.5 mg/kg bw dose group, the levels of sodium and chloride were significantly, dose-dependant, decreased compared to controls. No abnormalities were observed in the other groups. The level of protein and/or specific gravity were increased, but no marked differences between the groups were observed.
ORGAN WEIGHTS
In the 200 mg/kg bw dose group, increased spleen weights were observed in both sexes. Moreover, there were significant increases in the weight of lung and adrenals of males, significant decreases in salivary gland weights of both sexes and an increase in ovary weights additionally in the 50 mg/kg bw dose group.
GROSS PATHOLOGY
Swelling and thickening of capsule of the spleen and discolouration of the liver were evident in the highest dose group of both sexes. In addition, various other changes were observed in each group, but since there was no qualitative and quantitative difference to the control group, they were considered as not treatment-related.
HISTOPATHOLOGY: NON-NEOPLASTIC
Major histological changes were observed in the lung, spleen, liver, bone marrow and injection site of the tail. Foreign body embolisation in small muscular artery of the lung was occasionally found in the low and mid dose as well in the control group. They consisted of foreign body mutlinucleated giant cells and granulomas that contained har of the rats. Extremely remarkable granulomas in red pulp and vacuolisation were observed in the spleen of high dose goup animals of both sexes. Vacuolisation of red pulp looked like fatty vacuole degeneration. Diffuse granuloma was seen in all groups of both sexes, but no degeneration or congestion of hepatic cells was observed. Extreamedullary hemtopoiesis or congestion were observed. The bone marrow was infiltrated by granuloma in which megakaryocytes and reticulum cells were prominent in the highest dose group of both sexes. Increase of reticulum cells was characteristic. In addition, a part of the bone marrow was replaced by delicate connective tissue, fibroblasts and samll number of plasma cells and lymphocytes were also observed.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects reported up to this dose level.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.